seltorexant
Small moleculeexperimental
Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia. It is a selective antagonist of the orexin OX2 receptor (2-SORA). The medication is taken by mouth. — Wikipedia
Clinical trial activity
33 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
24
Phase 2
9
Phase 3
4
Phase 4
0
Earliest trial started Feb 1, 2014 (NCT02067299)
Timeline
Indications
Mechanism of action
- Orexin receptorANTAGONIST
Orexin receptor antagonist
- Orexin receptor 2ANTAGONIST
Orexin receptor 2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1- Mol. weight
- 407.45 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSeltorexant ↗
- ChEMBLCHEMBL3597971 ↗
Also known as
- jnj-42847922
- jnj-42847922
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06559306 | Phase 3 | Jul 25, 2024 | — |
| NCT05307692 | Phase 2 | May 19, 2022 | Johnson and Johnson |
| NCT05236868 | Phase 1 | Feb 3, 2022 | — |
| NCT05106153 | Phase 1 | Nov 5, 2021 | Janssen Pharmaceutica NV |
| NCT04951609 | Phase 1 | Sep 2, 2021 | Janssen Pharmaceutica NV |
| NCT04960124 | Phase 1 | Aug 5, 2021 | Janssen Pharmaceutica NV |
| NCT04616677 | Phase 1 | Dec 18, 2020 | Janssen Pharmaceutica NV |
| NCT04533529 | Phase 3 | Sep 16, 2020 | Janssen Pharmaceutica NV |
| NCT04513912 | Phase 3 | Sep 15, 2020 | Janssen Pharmaceutica NV |
| NCT04532749 | Phase 3 | Sep 15, 2020 | Janssen Pharmaceutica NV |
| NCT04553042 | Phase 1 | Sep 14, 2020 | Janssen Pharmaceutica NV |
| NCT04451187 | Phase 1 | Jul 16, 2020 | Janssen Pharmaceutica NV |
| NCT03796026 | Phase 1 | Jan 4, 2019 | Johnson and Johnson |
| NCT03682380 | Phase 1 | Oct 1, 2018 | Johnson and Johnson, Minerva Neurosciences |
| NCT03494907 | Phase 1 | Apr 9, 2018 | Johnson and Johnson |
| NCT03438461 | Phase 1 | Feb 9, 2018 | Johnson and Johnson |
| NCT03374475 | Phase 1 | Jan 5, 2018 | Johnson and Johnson |
| NCT03321526 | Phase 2 | Dec 12, 2017 | Johnson and Johnson |
| NCT03375203 | Phase 2 | Nov 23, 2017 | Johnson and Johnson |
| NCT03227224 | Phase 2 | Aug 16, 2017 | Johnson and Johnson, Minerva Neurosciences |
Showing 20 of 33 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 22 | 21 | 2 | 2014 |
| Janssen Pharmaceutica NV | For profit | 11 | 9 | 2 | 2014 |
| Minerva Neurosciences | For profit | 2 | 0 | 2 | 2017 |
3 organizations
Page 1 / 1